METTL3 and cancer: In bladder cancer, METTL3 was upregulated in patient samples, and it benefits cancer progression by mediating several m6A modification targets (CDCP1, ITGA6, AFF4, IKBKB, RELA, and MYC), in which YTH family served as the binding protein of the target transcripts (35–37).